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Abstract
Purpose The Cancer Vaccine Consortium of the Cancer
Research Institute (CVC-CRI) conducted a multicenter
HLA-peptide multimer proWciency panel (MPP) with a
group of 27 laboratories to assess the performance of the
assay.
Experimental design Participants used commercially
available HLA-peptide multimers and a well characterized
common source of peripheral blood mononuclear cells
(PBMC). The frequency of CD8+ T cells speciWc for two
HLA-A2-restricted model antigens was measured by Xow
cytometry.
The panel design allowed for participants to use their
preferred staining reagents and locally established proto-
cols for both cell labeling, data acquisition and analysis.
Results We observed signiWcant diVerences in both the
performance characteristics of the assay and the reported
frequencies of speciWc T cells across laboratories. These
results emphasize the need to identify the critical variables
important for the observed variability to allow for harmoni-
zation of the technique across institutions.
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1702 Cancer Immunol Immunother (2009) 58:1701–1713Conclusions Three key recommendations emerged that
would likely reduce assay variability and thus move toward
harmonizing of this assay. (1) Use of more than two colors
for the staining (2) collect at least 100,000 CD8 T cells, and
(3) use of a background control sample to appropriately set
the analytical gates. We also provide more insight into the
limitations of the assay and identiWed additional protocol
steps that potentially impact the quality of data generated
and therefore should serve as primary targets for systematic
analysis in future panels. Finally, we propose initial guide-
lines for harmonizing assay performance which include the
introduction of standard operating protocols to allow for
adequate training of technical staV and auditing of test anal-
ysis procedures.
Keywords HLA-peptide multimer · Tumor immunity · 
Flow cytometry · CTL
Introduction
A large number of clinical vaccination trials have been con-
ducted in the last 15 years in cancer patients [1]. Only a few
vaccine candidates, however, have advanced to phase III
clinical trials, and none have been approved so far [2].
Recent insights into the mechanisms that regulate immune
responses against tumors have led to the identiWcation of a
broad selection of compounds (antibodies, small-mole-
cules, cytokines, TLR ligands) that have the potential to
increase the eYcacy of vaccine regimens [3]. However, the
number of combinations that can be brought to advanced
stages of clinical testing is limited due to the complex
approval process for investigational new drugs. While it is
not possible to predict clinical outcome of therapeutic
tumor vaccination by results obtained from T cell immuno-
monitoring assays, development of validated surrogate
immunological end points for tumor vaccine activity and
ideally eYcacy could dramatically accelerate their clinical
development [4]. Consequently, the search for such surro-
gate immunological assays has become a high priority task
for the Weld.
For cancer vaccines, this search has led to the continuous
development of more powerful and sensitive assays to
monitor immune responses in vaccinated patients [5, 6].
Indeed, improved immunization strategies and new moni-
toring techniques have led to a steady increase of the frac-
tion of cancer patients with observed vaccine-related
immune responses [7–10]. Nevertheless, clinical responses
occur in a small fraction of patients, which may correlate
with the presence of a speciWc immune response [11–13].
The apparent disconnect between immunomonitoring data
and clinical events may be explained by several factors.
Measuring a single immune system parameter in one tissue
compartment, mostly IFN-gamma secreting T cells in the
peripheral blood, as is the case for the majority of clinical
trials thus far, might not be suYcient to capture an immuno-
logical signature correlating with the development of an
appropriate anti-tumor response. There is more and more
data suggesting that multiple functions of antigen-speciWc
T cells rather than, or in addition to, T cell numbers corre-
late with clinical outcome, as described in studies of protec-
tive immune responses to microbial infections in mice and
humans [14–16]. There is further evidence that classical T
cell assays will have to be used to measure responses in the
most appropriate tissue compartment [17, 18]. An addi-
tional important factor to consider for the observed lack of
correlation between results from immunomonitoring and
clinical events is the use of non standardized and non-vali-
dated immune monitoring assays. The use of such assays
precludes the direct comparison of results obtained by labs
across institutions [19] and also signiWcantly impacts the
ability to compare data obtained from diVerent patients and
time points within the same study. Thus, immune monitor-
ing assays need to be standardized, validated (or at a mini-
mum qualiWed) and auditable within laboratories before
they can be appropriately applied to evaluate samples
obtained from clinical trials. Finally, only qualiWed assays
can be used to eVectively guide the development of new
drugs [20] or serve as surrogate clinical endpoints.
Approximately 3 years ago, two international associa-
tions (CVC-CRI and the Association for Immunotherapy of
Cancer) initiated programs to address immune assay stan-
dardizations within the cancer scientiWc community [21]. A
similar eVort is ongoing in the Weld of infectious disease,
mainly driven by HIV-researchers [22]. The primary goals
of the CVC-CRI proWciency panel program are to allow for
the harmonization of immune monitoring assays across
institutions to a degree needed to represent stable bio-
marker assays and to provide for an external quality assur-
ance resource for laboratories participating in the
proWciency panel. The speciWc aims of the Wrst CVC-CRI
multimer proWciency panel presented in this manuscript
were to (1) demonstrate the feasibility of such large interna-
tional inter-laboratory testing project for HLA-peptide mul-
timers, (2) identify protocol variables, reagent choices and
strategies that are relevant in the formulation of harmoniza-
tion guidelines for assay protocol optimization (3) provide
each participating lab direct feed-back about their qualita-
tive and quantitative performance in relation to the other
members of the group (external-validation), (4) quantify the
variation of results reported by such a large number of labs
(inter-center variation), (5) determine the variation of
results obtained within the same lab using the same proto-
col to quantify antigen-speciWc CD8+ T cells with the same
samples doing the experiment at two diVerent time points
(intra-center variation).123
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Panel design
The Wrst CVC multimer panel was conducted with a group
of 27 centers. Each lab had to determine the frequency of
CD8+ T cells speciWc for two model antigens in cryopre-
served peripheral blood mononuclear cell (PBMC) sam-
ples from Wve donors (D1–D5). All participants used either
HLA-peptide tetramers or pentamers that were generously
donated by Beckman Coulter (Fullerton, CA) and Proim-
mune (Oxford, UK), respectively. Two labs used both
tetramers and pentamers and generated two separate data
sets. Consequently, we were able to collect 29 complete
data sets in a Wrst step of testing. All participants were
further oVered the possibility to receive a second set of
PBMC batches to allow for repetition of the experiments
in a second step. Nine of the 27 labs made use of this oVer
and completed a second round of testing of the same
PBMC samples with one lab contributing two separate
data sets.
Participants and organizational setup
Participating laboratories were located in eight countries
(Belgium, Canada, Germany, France, Sweden, Switzerland,
UK, and USA). Each laboratory received an individual lab
ID number. Panel leadership was provided by two scientiWc
leaders experienced in MHC-peptide multimer staining, in
collaboration with the CVC executive oYce. The Lausanne
branch of the Ludwig Institute for Cancer Research (LICR-
LB) performed extensive pre-testing of donor samples and
selection of appropriate donors.
PBMCs and peptides
PBMCs from healthy donors were obtained from a com-
mercial donor bank and processed under GMP conditions
using established standard operating procedures at Cellular
Technologies Limited (CTL), Cleveland, OH. PBMCs were
frozen using a rate controlled freezer and transferred to the
vapor phase of liquid nitrogen. Cell separation procedure
and freezing of cells were conducted under validated condi-
tions. It was demonstrated that functionality and viability
were maintained throughout the procedure. Each vial of
PBMCs contained enough cells to ensure a recovery of
10 million cells or more under CTL’s SOP. Cells were
shipped to all participants for overnight delivery on suY-
cient dry ice for 48 h for centers within the USA. Centers
located in Europe and Canada received cells shipped in dry
shippers Wlled with suYcient liquid nitrogen to assure cell
integrity for up to 7 days. Shipment of cells was performed
by CTL under their existing SOPs.
PBMCs were pretested at the LICR-LB for reactivity
against the HLA-A2-restricted InXuenza-M158–66 (antigen
“A1” = GILGFVFTL) [23] and Melan-A/Mart-126–35A27L
(antigen “A2” = ELAGIGILTV) [24]. PBMCs from Wve
donors were selected for no, low, medium and strong
responses against the two tested antigens. Pre-testing was
performed by generating three independent data sets using
HLA-peptide tetramers (Beckman Coulter Immunomics),
HLA-peptide pentamers (ProImmune) and HLA-peptide
tetramers manufactured at the LICR-LB for research use.
For the proWciency panel testing, MHC-peptide tetramers
(Beckman Coulter) and pentamers (Proimmune) speciWc
for both model antigens were provided in suYcient amount
to perform 50 stainings per center and had to be applied as
10 l volume per staining. All cells and reagents sent to
participants in both panels were obtained from the same
batches.
HLA-peptide multimer staining
One of the main features of the Wrst CVC multimer panel
was that all participants (in both steps) used their preferred
reagents and locally established protocols to determine the
percentage of antigen-speciWc CD8+ T cells. The only
requirement was to use the HLA-peptide multimers pro-
vided by the respective commercial sources. Moreover, the
organizers avoided oVering recommendations, providing
protocols, or asking for any other measure of harmoniza-
tion.
Statistical analysis
The following parameters were calculated for both the
overall panel and the individual participant’s performance,
using the lab-speciWc reported percentage of multimer-
positive CD8-positive cells: the mean, standard deviation,
and coeYcient of variation (CV), the median, 25th and 75th
percentiles, minimum, and maximum percentage of CD8-
positive cells for each donor and antigen.
Due to the extreme variation of the reported values we
applied two data Wlters to remove a large proportion of non
meaningful results from the Wnal analysis. The Wrst Wlter
was based on the coeYcient of variation (CV) from the rep-
licates within a lab for a given donor and antigen and used
to eliminate outlier replicate values from the Wnal analysis.
Data sets with either replicate that had a CV greater than 75
or only one measurement for a given donor and antigen
combination did not pass this Wlter. The second Wlter was
based on the dot plots generated from the lab’s analysis of
the Xow cytometer results. An independent evaluator exam-
ined all the dot plots and assigned a score based on the clus-
tering of positive events. A score of 0 was given when there
was no clustering, a score of 1 for ambiguous results, and a123
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positive events in the upper right quadrant. Labs with repli-
cates that had a total score of less than 4 did not pass this
Wlter. Therefore, there had to be at least one staining with
clear clustering from a given replicate to pass the Wlter.
Labs that passed both Wlters were considered to have
detected a response for that donor and antigen. The associa-
tion between detected response rate and number of counted
CD8+ T cells was tested using the Chi square test.
The questionnaire responses outlining the various proto-
cols used by all the labs were summarized using frequency
tabulations. The following parameters were calculated to
summarize the overall recovery and viability for each of the
thawed PBMC donor samples: mean, median, minimum,
and maximum.
For laboratories that participated in the second step, the
individual laboratory results from the second step were pre-
sented in the same format as in the Wrst step. Within an
individual laboratory, the results from the two steps were
compared by calculating the percent diVerence from the
Wrst step, the standard deviation of the means from both
steps and the corresponding coeYcient of variation (CV).
The average CV across the ten donor antigen combinations
was computed as a general indication of how similar the
results were in the same laboratory at two diVerent time
points.
Results
All 27 participating centers received the necessary PBMC
samples, commercially available HLA-peptide multimers
and instructions, and were able to perform the requested
stainings. A total number of 29 expected questionnaires,
report forms and dot plots were successfully collected for
analysis via a web-based database speciWcally designed to
administer and process large amount of data from immune
monitoring assays. The organizers also received and ana-
lyzed ten complete data sets from the second step. After
each step individualized reports were provided to all partic-
ipating labs.
Human auditing process of Wnal results
Before Wnal analysis, all collected data sets were screened
for obvious failures and inconsistencies. These included
incorrect gating by some participants, uneven quality of
electronic compensation of Xow cytometry based event
acquisition (Figs. 1a, b, 2b) and aberrant reported values
from two data sets that did not reXect the number of events
shown in the corresponding dot plots. The latter originated
in a systematic error when entering the event counts for all
four quadrants into the spread sheet (not shown). Together,
these Wndings emphasize the importance of systematic
auditing of assay results.
Overview of assay protocols currently in use 
at the international level
Each participant provided detailed information about
experimental protocol and reagents used. It became clear
that multimer labeling is currently performed using a broad
variety reagents and procedures. Supplementary table 1
which is available online shows the distribution of labs for
11 variables with the potential to inXuence the sensitivity of
the multimer labeling assay (multimer source, use of
DNAse during thawing, counting method, type of Xow
cytometer used, staining performed in tubes or plates, con-
jugate staining order, number of Xuorochromes, method for
dead cell exclusion, anti-CD3 staining, use of a dump chan-
nel and antibodies used for co-staining) and provides a
comprehensive overview of the protocols that were applied.
When looking at a distinct subgroup of labs sharing one
variable, it became clear that the expression of the other ten
variables was still randomly distributed within the sub-
groups.
Inter- and intra-center variation
For our group of 27 laboratories we found an unexpectedly
high variation among the reported 29 datasets for eight of
the ten diVerent donor antigen combinations with CVs
ranging from 47 to 158 (Table 1). This was the case even
for the three highest responses (InXuenza in D2/D4/D5 with
corresponding CVs of 47.2/93.7/57.1). The even higher
variation found in donor 1 result from the fact that no or
extremely low number of antigen-speciWc T cells were
present in this donor. The liberal design of this panel
provides a measure of the variation of results that may be
representative of current immune monitoring of antigen-
speciWc CD8+ T cell responses using the multimer-based
assay.
It is well established that the validation process of any
diagnostic test, including cellular assays, should include
the prior determination of accuracy, speciWcity, sensitiv-
ity, reliability, linearity and range determination as well
as important precision parameters such as the intra-assay
and inter-assay variation of results [25]. Nine labs
repeated the panel at a separate time point. As one center
generated two separate data sets with HLA-peptide tetra-
mers as well as pentamers the whole group submitted ten
complete datasets. In order to quantify the intra-lab varia-
tion we calculated the mean CD8+ speciWc T cell binding
at each time and compared these means by determining
the absolute and percentage-wise diVerence between the
results from both steps (not shown) as well as the123
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in Supplementary table 2). Five participating centers
reported pairs of results that were very close to each other
(average intra-center CV < 30) for most of the eight
depicted antigen-donor combinations showing that repro-
ducibility within an acceptable range can be obtained for a
broad range of detected antigen-speciWc T cell responses.
The other Wve laboratories reported results for step 2 that
were quite diVerent from step 1 (average intra-center
CV > 30). Consequently, intra-center variation was unex-
pectedly large for these labs.
Limitations of the multimer assay
A small group of Wve centers were able to detect a small but
distinct population of InXuenza-M1-speciWc CD8+ cells in
donor D1 and reported an average value of 0.11% multi-
mer-positive CD8+ T cells in this donor. Representative dot
plots are shown in Fig. 2a–e. On the other hand none of the
participating centers was able to detect Melan-A/Mart-1-
speciWc CD8+ T cells in the same donor. We made use of
the reported data from this donor to get more insights into
the technical limitations of the technology. Our aim was to
determine if the reported mean value of 0.11% InXuenza-
M1-speciWc CD8 T cells could indeed be considered as
being above the normal variation of the background usually
found in an average lab. ID21 set the analytical gates in
such a way that a high number of clearly multimer-negative
events fell into the upper right quadrant (Fig. 2d, Supple-
mentary Wgures 1 and 2). ID22 used an atypical gating
strategy which removed dead and CD8-negative cells and
reported an extremely low background of non-speciWc mul-
timer staining (Supplementary Wgure 2a). Three centers
(ID05, ID17 and ID20) used a classical gating strategy and
reported values for the non-speciWc binding of the Melan-
A/Mart-1 multimer that were similar to results obtained by
a large number of other participants and therefore appropri-
ately represent the background staining normally found in a
number of commonly used protocols (Supplementary
Wgure 2a). These three centers reported a mean of 0.06%
multimer-positive CD8+ T cells using the Melan-A/Mart-1
multimer in donor 1 with a standard deviation of 0.01%
(Fig. 2f). Based on these results we roughly estimated a
limit of detection (LOD) of 0.09% which resulted from
adding three times the standard deviation to the mean. In
addition we estimated a limit of quantiWcation (LOQ) of
0.16% which resulted from adding ten times the standard
deviation to the mean.
Fig. 1 The Wgure shows eight selected examples (a–h) of dot plots
where gating led to reporting of increased number of events in the
upper right quadrant. All dot plots show the CD8-staining on the
x-axis and the staining with the HLA-peptide multimer on the y-axis.
Dot plots were chosen from laboratories ID01, ID10, ID28 and ID30.
Under each dot plot the expected versus the reported (underlined)
frequency of multimer-positive CD8 cells is indicated
ID01
(a) (b)
ID28
(c) (d)
CD8
M
ul
tim
er
0.05% vs. 2.19%0.33% vs. 1.6% Negative vs. 0.3% 0.07% vs. 1.14%
ID10
(e) (f)
ID30
(g) (h)
0.19% vs. 1.78% 0.19% vs. 0.792% 0.1% vs. 0.719%0.15% vs. 1.87%123
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17, 20, 21 and 22 reported for staining samples from donor1 with the
InXuenza-M1 multimer. *Center ID21 set the analytical gate in such a
way that multimer-negative cells are shown in the upper right
quadrant. **Center ID22 used an atypical gating strategy in which
CD8-negative cells were removed at an earlier step of the analysis.
The inserted table (f) shows reported values for non-speciWc binding
of the Melan-A/Mart-1-speciWc multimer in samples from triplicate
analysis (T1, T2 and T3) of donor 1 performed by centers ID05, 17 and
20
(a) ID05 (b) ID17 (c) ID20
(d) ID21* (e) ID22*
M
ul
tim
er
CD8
(f) ID Mult+CD8+
ID05 T1: 0.07 %
ID05 T2: 0.08 %
ID05 T3: 0.05 %
ID17 T1: 0.06 %
ID17 T2: 0.06 %
ID17 T3: 0.05 %
ID20 T1: 0.07 %
ID20 T2: 0.05 %
ID20 T3: 0.05 %
CD8
0.90
19.84
0.11
79.15
0.02
79.28
0.02
20.68
0.30
70.30
0.10
29.30
Melan A was removed
0.03
79.44
0.01
20.52
0.00
0.00
0.04
99.96 %ages were added in a-e
Table 1 Percentage of CD8-speciWc multimer binding based on the mean of the triplicates
The table shows the overall results (median, 25th, 75th percentile, mean, standard deviation, coeYcient of variation, minimum and maximum) for
all ten antigen-donor combinations reported by the whole group
a Donor 1 was considered to have a very low response against InXuenza-M1 which was below the limit of quantiWcation
b Donor 1 was considered to have no detectable response against Melan-A/Mart-1
Antigen Donor Median 25th Percentile 75th Percentile Mean SD CV Min Max
InXuenza-M1 D1 0.07 0.04 0.15 0.32 0.67 210.58a 0.00 2.87
D2 0.67 0.50 0.89 0.73 0.34 47.16 0.24 2.05
D3 0.16 0.11 0.32 0.29 0.35 122.95 0.00 1.53
D4 0.19 0.17 0.27 0.28 0.26 93.66 0.07 1.44
D5 0.35 0.31 0.41 0.44 0.25 57.05 0.21 1.21
Melan-A/Mart-1 D1 0.07 0.03 0.19 0.23 0.48 207.48b 0.00 2.53
D2 0.10 0.03 0.17 0.17 0.27 156.14 0.00 1.30
D3 0.12 0.06 0.23 0.25 0.40 157.76 0.02 2.09
D4 0.10 0.04 0.15 0.17 0.23 135.44 0.01 1.06
D5 0.08 0.03 0.17 0.18 0.26 142.63 0.01 1.06123
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A total of nine positive responses could have been detected
in the Wve donors (for all details see Table 2) from which 1
was considered to be below the estimated limit of quantiW-
cation (deWned as <0.16%), 2 were low (deWned as <0.2%),
5 were moderate (deWned as ¸0.2 and ·0.5%) and 1 was
high (deWned as >0.5%). Table 1 indicates the median,
25th, 75th percentile and mean, for each of the ten measure-
ments. The report from the Wrst step of the panel displayed
the percentages for antigen-speciWc CD8+ cells from all 29
protocols for all ten antigen-donor combinations (Supple-
mentary Wgures 1 and 2).
To deWne if a participant had successfully detected a
response, two acceptance criteria were introduced and
applied. On one hand, replicates were excluded from fur-
ther analysis when they had a high variation (deWned as
CV > 75). A total of 24 replicates (8.2%) were found to
have unacceptably high variation and were therefore
rejected (details are shown in Supplementary table 3). On
the other hand, replicates that did not show clear and clus-
tered populations of events in the upper right quadrants
indicating CD8+ multimer+ cells, as assessed by an inde-
pendent evaluator, were also excluded (details are shown in
Supplementary table 4). Due to this rule a total of 101 repli-
cates (34%) were discarded. Based on this deWnition of
response, the whole group was able to detect 66% of all
possibly detectable responses, with some labs not able to
detect any responses and only a few detecting all nine
responses (Table 3). Donor D1 with Melan-A/Mart-1 was a
negative control donor. No lab reported a false positive
response for this antigen-donor combination. Supplementary
Wgure 3, which is also available as electronic supplemen-
tary material, shows selected results from the optical evalu-
ation to allow the reader to discern the amount of clustering
that was considered to be clearly negative (0), ambiguous
result (1) or clearly positive (2). The Wgure also makes clear
that optical evaluation of dot plots is a very subjective
approach as an objective deWnition of a “clustered popula-
tion” does not exist. Consequently, interpretation of results
by optical evaluation should be regarded with caution,
especially when very small populations are judged. How-
ever, one independent evaluator examined and rated all of
the dot plots and applied the same criterion to all dot plots.
Hence, there was a uniform criterion applied to all dot plots
even though a subjective deWnition was used.
Subgroup-analysis
One aim of the CVC multimer panel was to deduce recom-
mendations for initial harmonization guidelines of the
assay. One clear Wnding from the panel was that the number
of CD8+ cells counted per replicate critically determines
the chance that an immune response is detected. The major-
ity of results were based on collection of 30,000–100,000
CD8 positive (CD8+) events. In the subgroup in which less
than 10,000 CD8+ cells were collected, only 13% detected
a response (Table 4). In contrast, 87% of replicates with
more than 100,000 accumulated CD8+ cells detected a
response correctly. There was a statistically signiWcant
diVerence (P = 0.001, Chi square test) when comparing the
response detection rates in triplicates with at least 100,000
CD8+ cells counted (39/45 = 87%) versus less than
100,000 CD8+ cells counted (133/218 = 61%).
We then focused only on the results obtained for the four
lowest responses (Melan-A/Mart-1 response for donors D2,
D4 or D5 and InXuenza-M1 response for donor D1). The
lower part of Table 4 shows that 12% (4/33) of the lower
Table 2 Expected percentage of antigen-speciWc CD8 T cells within
the distributed samples
The table shows that a total of eight positive responses could have been
detected in the Wve donors (D1–D5) from which one was above the
LOD value but below the LOQ value, two were considered as being
low (deWned as <0.2%), Wve were moderate (deWned as ¸0.2 and
·0.5%) and one was high (deWned as >0.5%)
Antigen Donor Frequency Response
InXuenza-M1 D1 0.11 >LOD and <LOQ
D2 0.76 High
D3 0.26 Moderate
D4 0.28 Moderate
D5 0.39 Moderate
Melan-A/Mart-1 D1 0.00 Negative
D2 0.22 Moderate
D3 0.31 Moderate
D4 0.19 Low
D5 0.16 Low
Table 3 Number of labs that detected each possible number of accept-
ed responses
The table shows the summary of the distribution of the number of times
a lab was considered of having detected a response
No. of detected responses No. of labs Percentage
0 2 7
1 1 3
3 3 10
4 1 3
5 2 7
6 5 17
7 5 17
8 7 24
9 3 10123
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positive CD8+ cells counted, whereas 80% were detected
by triplicates with more than 100,000 CD8+ cells counted.
There was a statistically signiWcant diVerence (P = 0.001,
Chi square test) when comparing the response detection
rates in triplicates with at least 100,000 CD8+ cells
counted (16/20 = 80%) versus less than 100,000 CD8+
cells counted (38/96 = 40%).
A second source of variation was related to electronic
gate setting during data analysis. Most of the labs that
reported out of range high values of speciWc multimer bind-
ing did so because they set the gates too low thereby
increasing the number of dots on the upper right quadrant
(Fig. 1). Thus, a method that helps setting the gates cor-
rectly would lead to a reduction of the inter-lab variation.
Although the majority of labs (66%) were not able to
detect eight or nine responses, ten of the participating labs
were able to do so. Analysis of the protocols used by these
ten high performing labs indicated that comparable results
could be obtained with protocols that diVered widely from
each other (not shown). For instance, high performing labs
were found among those that (1) reported low or high cell
viability after thawing, (2) used tetramers as well as penta-
mers, (3) used or did not use DNAse for thawing, (4) used
manual or automated cell counting methods, (5) stained in
tubes or in plates, (6) Wrst stained with the multimer or
simultaneously stained with multimer and antibodies for
co-staining, (7) used three or four Xuorochromes, (8) used
or did not use dead cell staining, (9) used or did not use
anti-CD3 staining, (10) used or did not use a dump channel,
or (11) reported low, medium or high values for non-spe-
ciWc multimer binding. The only subgroup that did not
include any of the ten high performing labs was the one that
only used two Xuorochromes (anti-CD8 vs. HLA-peptide
multimer) for the staining (two laboratories).
To identify additional variables that may inXuence the
sensitivity of the assay, we used the results from the ques-
tionnaires to deWne 2–3 subgroups for 11 protocol vari-
ables. We then compared the ability to successfully detect
one of the nine responses for all diVerent subgroups of labs.
Supplementary table 5 summarizes the lab characteristics
and reports the number of detected responses and the aver-
age proportion of detected responses for each subgroup.
Responses were more likely to be detected if labs had more
than 75% viability (vs. less than 75%), used pentamers (vs.
tetramers), used DNAse (vs. no DNAse), used a manual
counting method (vs. machine), did multimer and then co-
staining (vs. simultaneously), used three or four colors (vs.
two colors), did not do CD3 staining (vs. did CD3 staining)
or used a dump channel (vs. no dump channel). It is impor-
tant to stress that the labs within each subgroup applied pro-
tocols that diVered widely from each other. This means that
diVerences found between some of the subgroups in our
panel do not formally prove that the variable that was
selected to deWne the subgroup was the deWning factor that
inXuenced the performance of those labs. Although we
were not able to deduce additional recommendations from
this analysis we classify the subgroups that showed the
highest diVerences as interesting targets for more system-
atic analysis in future proWciency panels.
Discussion
The speciWc aims of the Wrst CVC-CRI multimer proW-
ciency panel presented in this manuscript were to establish
the foundations for developing a robust and validated MHC
multimer assay which can be harmonized across immune
monitoring laboratories by: (1) demonstrating the feasibil-
ity of such large international inter-laboratory testing pro-
ject for HLA-peptide multimers, (2) identifying protocol
variables, reagent choices and strategies that are relevant
for assay protocol optimization (3) providing each partici-
pating lab direct feed-back about their qualitative and quan-
titative performance in relation to the other members of the
group, (4) quantifying the variation of results reported by
such a large number of labs (inter-center variation), and (5)
determining the variation of results obtained within the
Table 4 Number of CD8-positive cells counted and proportion of
responses detected
The table shows the average number of CD8-positive cells counted for
a given replicate and the proportion of responses detected within the
speciWed counting range (Wrst column). The mean number of CD8+ T
cells counted per replicate was calculated and all tests were attributed
to one of four groups (<10,000/10–30,000/30–100,000/>100,000). The
table shows the total number of responses and the percentage of
responses detected by labs in each of the four groups. The upper half
of the table shows the results from all ten donor antigen combinations.
The lower half of the table displays the results of testing for the four
lowest responses in the distributed samples (Melan-A/Mart-1 response
for donors D2, D4 or D5 and InXuenza-M1 response for donor D1)
Number of 
CD8-positive 
cells
Number of 
triplicates
Number of 
responses
Responses 
(%)
<10,000 32 4 13
10–30,000 40 24 60
30–100,000 144 105 73
>100,000 45 39 87
Number of 
CD8-positive 
cells
Number of 
triplicates
Number of 
low responses
Low responses 
(%)
<10,000 15 0 0
10–30,000 18 4 22
30–100,000 63 34 54
>100,000 20 16 80123
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doing the experiment at two diVerent time points (intra-
center variation).
The results from this panel demonstrated the feasibility
of such a large inter-laboratory testing project for MHC-
peptide multimer staining. Importantly, they reveal the
wide variety of diVerent protocols and strategies used with
multimers, which appears representative of the most com-
monly used protocols worldwide. This unique situation
allowed us to determine the average amount of non-speciWc
multimer binding normally observed in a broad range of
commonly applied protocols (Fig. 2f, Supplementary
Wgure 2a). Based on these data we estimated an LOD and
LOQ. Such performance-related thresholds determined by
data sets obtained in large-scale quality assurance programs
are valuable tools to more objectively rank the performance
of participating labs and might be used for assay certiWca-
tion purposes in the future.
The results obtained in this CVC-CRI multimer panel
allowed, for the Wrst time, the quantiWcation of the actual
variation in results between diVerent labs across the United
States and Europe. The high inter- and intra-center varia-
tion were unexpected and stand in contrast to a report from
a smaller European group [26]. Although the performance
of cellular immunoassays tested in single centers or within
selected groups that either used one common protocol [27]
or went through intensiWed validation and harmonization
steps appears quite robust [28, 29], it is important to point
out that the performance of this assay in a non-selected
group of labs is clearly not robust and results are subject to
a large degree of variation. The results generated by this
large international panel can now serve the scientiWc com-
munity as a benchmark for future similar projects. Every
newly introduced measure to harmonize the technique
should lead to a reduction of the variation found in this
panel.
Our results emphasize the urgent need for harmonization
of the multimer labeling technique. Despite this conclusion,
it is important to state that the presented data should not be
used to justify the non-critical discarding of data obtained
by HLA-peptide multimer staining. Recently a systematic
analysis of cellular based immunoassays clearly showed
that ELIPOT, cytokine Xow cytometry as well as HLA-pep-
tide multimer staining can be used to precisely and stably
quantify antigen-speciWc T cell responses within a broad
range of frequencies within highly validated laboratories
[30]. The fact that a third of the labs involved in this proW-
ciency panel were able to detect eight or nine of all
responses included in the distributed samples and that Wve
out of ten labs were able to (qualitatively and quantita-
tively) reproduce their results in a second step throughout a
broad range of T cell responses of diVerent frequencies
demonstrate that staining with HLA-peptide multimers is a
sensitive technique that can be reliably used to quantify
antigen-speciWc T cells in clinical trials. At the same time,
these observations pose major challenges for assay harmo-
nization as it is clear that two-thirds of the labs involved
had diYculty in accurately and reproducibly measuring
speciWc T cell frequencies.
Initial harmonization guidelines to improve assay 
performance
Based on the results of this multimer panel, we outline ini-
tial assay harmonization guidelines addressing four areas of
immunomonitoring by HLA-peptide multimers (Table 5).
These guidelines include basic recommendations (a) for the
staining procedure, (b) the analysis of data, (c) the auditing
of data obtained before they are released and (d) the qualiW-
cation of staV members involved in the analysis. Use of
these guidelines may substantially reduce assay variability
while allowing individual laboratories to use their respec-
tive assay protocols.
Standard operating procedure for HLA-peptide 
multimer staining
Three clear recommendations for the staining procedure
can be deduced from the analysis of inter-laboratory result
variation. These are to (1) use of a protocol that includes
more than two colors for staining, (2) evaluate at least
100,000 CD8+ T cells and (3) use a background control to
set the gates.
Although a simple two-color staining is adequate to
characterize the HLA-peptide multimer binding capacity of
T cell lines or clones, it is clear that such a simple protocol
does not allow reliable quantiWcation of the frequency of
antigen-speciWc T cells in peripheral blood specimens
which include non CD8 T cell subsets that either speciWcally
Table 5 MHC-peptide multimer harmonization guidelines to opti-
mize assay performance
(A) Establish lab SOP for MHC-peptide multimer staining
A1 Count at least 100,000 CD8 T cells per staining
A2 Introduce a background control to set gates
A3 Use more than two colors for staining
(B) Establish SOP for software analyses of stained samples, including
B1 Gating strategy
B2 Rules to set the gates
(C) Establish a human auditing process of all Wnal results
C1 Are all dot plots correctly compensated?
C2 Have the gates been set correctly?
C3 Are the calculated frequencies of multimer-positive 
cells plausible?
(D) Only let well trained personnel (per lab SOP) conduct assay123
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CD8 T cell speciWc staining becomes a major problem
when low frequencies of antigen-speciWc T cells need to be
visualized, which is the case for ex vivo detection of most
virus-speciWc T cell responses that are regularly found to
represent less than 1% of CD8+ T cells in chronic viral
infections [31] or tumor-speciWc T cells that are present in
even lower numbers [32, 33]. One clear recommendation
from this panel is to use additional Xuorochromes and
establish a methodology which minimizes background; this
conclusion is supported by an earlier report elaborating the
relevant factors for staining with HLA-peptide multimers
[34]. The use of additional Xuorochromes is technically fea-
sible and easily allows gating to remove dead cells, B cells,
monocytes, CD4+ cells or NK cells to focus more speciW-
cally on the cell population of interest, thereby reducing the
chance of displaying cells that all can contribute to non-rel-
evant events.
The second recommendation to increase the number of
counted cells conWrms data from an inter-laboratory com-
parison of diVerent labs conducted by the European CIMT
Monitoring panel [35] demonstrating the high impact of
this parameter.
A strategy that helps to set gates correctly would prevent
the errors found in this panel and may lead to greatly
reduced inter-laboratory variation and optimized levels of
detection and quantiWcation as these critically depend on
the observed background noise. In this regard, the use of a
“negative” control staining to deWne the background multi-
mer labeling remains controversial. Centers that already
apply negative control stainings use one of the following
three strategies. (1) Fluorescence minus one (“FMO”) sta-
inings that include all antibodies/dead cell markers but no
HLA-peptide multimer. (2) Negative control stainings with
HLA-peptide multimer speciWc for well deWned peptides
from human immunodeWciency virus (HIV). (3) Commer-
cially available preparations of irrelevant HLA-peptide
multimers. An alternative strategy may be to search for new
negative control peptides and to systematically test HLA-
peptide multimers containing these putative candidates for
their suitability as negative controls in patients with cancer,
infectious and autoimmune diseases. All strategies that are
commonly used to deWne background of HLA-peptide mul-
timer staining have speciWc advantages and disadvantages
and as yet they have not been systematically compared with
each other. Regardless, it is clear that the use of a negative
control for deWning the background staining of HLA-pep-
tide multimers should be applied as a guide for standard-
ized gate setting. Valuable software solutions that apply
mathematical algorithms to set gates independent of the
operator’s subjective view are in development but are so far
not available for broad use [36].
In addition to these three initial recommendations we
identiWed primary targets for systematic analysis in future
panels that have a high probability to inXuence test sensitiv-
ity (Supplementary table 5). The inXuence of these vari-
ables will be systematically addressed in future proWciency
panels.
Training of staV members
Although the staining with MHC-peptide multimers seems,
at Wrst sight, to be a simple and straightforward procedure,
our results have shown that even the use of one and the
same batch of HLA-peptide multimers can lead to diVerent
results if applied in diVerent staining protocols. The high
values for intra-center variability detected in Wve from ten
labs participating in a repetition of the experiment showed
that even when a staining is repeated in the same lab by
using the same protocol it does not automatically lead to
similar results (Supplementary table 2). Each step, from the
collection of cell material to reporting of results, adds
sources for variation which separately contribute to the var-
iation of results obtained either by diVerent labs worldwide
or from measurements by the same lab at diVerent time
points. It is thus necessary that staV members performing
the measurements should be aware of the sources of varia-
tion within their responsibility and be trained in all mea-
sures that need to be taken to keep variation as low as
possible. The regular and speciWc education of staV mem-
bers and mechanisms to control their performance are well
established and mandatory requirements for all laboratories
working under rules deWning a good manufacturing prac-
tice but have so far not been systematically applied for
immunomonitoring of clinical samples. In a previous ELI-
SPOT proWciency panel conducted by the CVC, it could be
shown that establishing SOPs for assay validation and staV
training clearly lead to an increased performance of partici-
pating labs [37]. We therefore propose to implement for-
malized assay speciWc education of all staV members
involved in immune monitoring with HLA-peptide multi-
mers before clinical material should be allowed to be pro-
cessed.
In conclusion, our study reveals the variety of HLA-pep-
tide multimer-based assay formats currently in use in the
tumor immunology and immunotherapy community. More-
over, it has allowed us to measure the magnitude of both
inter and intra-laboratory result variation. We have gained
detailed insight into technical limitations of commonly
applied protocols and provide estimates for expectable lim-
its of detection and quantiWcation. Finally, valuable recom-
mendations could be derived that should guide the future
assay harmonization eVorts spearheaded by the CVC-CRI
as well as other consortia active in this domain.123
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